
FUNDING POLICY REVIEW

BOARD MEETING
Marta Tufet Bayona
Emmanuel Bor
24-25 July 2025, Geneva, Switzerland



Gavi's funding policies revised to ensure fit-forpurpose in 6.0 – final stage of Funding Policy Review





Revised Health System and Immunisation Strengthening (HSIS) Policy

Approved policy shifts in December 2024

- Consolidation of funding levers into one HSIS grant
- **2. Guardrails** to safeguard key investments
- 3. Revised allocation approach:
 - Revised allocation formula
 - Holistic planning, including NVIs, switches, etc.
- 4. Approach to promote **government health systems co-investment**



CSO guardrail: 10% minimum allocation



Minimum floor based on alliance forecast of **Cold Chain Equipment** needs



Guardrail for Measles/Measles-Rubella follow-up campaigns

Further developed since December 2024



CCE Country Joint Investment (CJI): Maintaining and improving the CJI model



Reduction of support for routine operational





Development of learning agenda for HSS domestic co-investment options in 6.0



Further developed policy shifts since December 2024

A guardrail for M/MR follow-up campaigns

To prevent measles immunity gaps and outbreaks, over/under spending and provide visibility for countries.

Countries are required to:

- 1 Spend within the communicated guardrail range (US\$ X to US\$ Y), which will be based on Gavi 6.0 forecasts
- 2 Conduct M/MR follow-up campaigns as per WHO guidance
- 3 Align timing of MR catch-up campaigns with follow-up campaigns

Promoting government co-investments in health systems

Policy parameters on routine operational costs

Guardrails for countries in preparatory and accelerated transition phased in over time


Building budgetary capacity through improved Cold Chain Equipment joint investment model

Flexible payment modalities and schedules, differentiated and lower requirements, systematic approach to waivers, and introduction of consequences for non-compliance



Gavi's enhanced Eligibility and Transition model

Projected Increase in Co-financing: From 16% of Vaccine Costs in 5.0 to 24% in 6.0



per dose for all NVIs in PT and AT

Backsliding prevention and mitigation

Recommendations

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) Approve the revised Eligibility and Transition Policy attached as Annex A to Doc 06;
- b) <u>Approve</u> the revised Co-financing Policy attached as Annex B to Doc 06, as amended by discussions at the PPC;
- c) <u>Approve</u> the revised Health Systems and Immunisation Strengthening (HSIS) Policy attached as Annex C to Doc 06; and
- d) <u>Approve</u> a minimum co-financing threshold of US\$ 0.20 for the introduction of Hepatitis B birth dose and DTP booster in countries in preparatory and accelerated transition.





Thank you